Prophylactic platelets in dengue: survey responses highlight lack of an evidence base

Article English OPEN
Whitehorn, J ; Rodriguez Roche, R ; Guzman, MG ; Martinez, E ; Gomez, WV ; Nainggolan, L ; Laksono, IS ; Mishra, A ; Lum, L ; Faiz, A ; Sall, A ; Dawurung, J ; Borges, A ; Leo, YS ; Blumberg, L ; Bausch, DG ; Kroeger, A ; Horstick, O ; Thwaites, G ; Wertheim, H ; Larsson, M ; Hien, T ; Peeling, R ; Wills, B ; Simmons, C ; Farrar, J (2012)
  • Publisher: Public Library of Science
  • Journal: PLoS neglected tropical diseases, volume 6, issue 6 (issn: 1935-2727 1935-2727, eissn: 1935-2735)
  • Related identifiers: doi: 10.1371/journal.pntd.0001716, pmc: PMC3383756
  • Subject: Global Health | wb_356 | Research Article | Neglected Tropical Diseases | wh_300 | Infectious Diseases | wc_528 | Medicine | Viral Diseases

: Dengue is the most important arboviral infection of humans. Thrombocytopenia is frequently observed in the course of infection and haemorrhage may occur in severe disease. The degree of thrombocytopenia correlates with the severity of infection, and may contribute to the risk of haemorrhage. As a result of this prophylactic platelet transfusions are sometimes advocated for the prevention of haemorrhage. There is currently no evidence to support this practice, and platelet transfusions are costly and sometimes harmful. We conducted a global survey to assess the different approaches to the use of platelets in dengue. Respondents were all physicians involved with the treatment of patients with dengue. Respondents were asked that their answers reflected what they would do if they were the treating physician. We received responses from 306 physicians from 20 different countries. The heterogeneity of the responses highlights the variation in clinical practice and lack of an evidence base in this area and underscores the importance of prospective clinical trials to address this key question in the clinical management of patients with dengue.
  • References (15)
    15 references, page 1 of 2

    1. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8: S7-S16.

    2. Lee VJ, Lye DC, Sun Y, Fernandez G, Ong A, et al. (2008) Predictive value of simple clinical and laboratory variables for dengue hemorrhagic fever in adults. J Clin Virol 42: 34-39.

    3. La Russa VF, Innis BL (1995) Mechanisms of dengue virus-induced bone marrow suppression. Baillieres Clin Haematol 8: 249-270.

    4. Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, et al. (2001) Immunopathogenesis of dengue virus infection. J Biomed Sci 8: 377-388.

    5. Alonzo MT, Lacuesta TL, Dimaano EM, Kurosu T, Suarez LA, et al. (2012) Platelet apoptosis and apoptotic platelet clearance by macrophages in secondary dengue virus infections. J Infect Dis 205: 1321-1329.

    6. Krishnamurti C, Kalayanarooj S, Cutting MA, Peat RA, Rothwell SW, et al. (2001) Mechanisms of hemorrhage in dengue without circulatory collapse. Am J Trop Med Hyg 65: 840-847.

    7. Noisakran S, Chokephaibulkit K, Songprakhon P, Onlamoon N, Hsiao HM, et al. (2009) A re-evaluation of the mechanisms leading to dengue hemorrhagic fever. Ann N Y Acad Sci 1171 Suppl 1: E24-35.

    8. WHO (2009) Dengue: guidelines for diagnosis, treatment, prevention and control - New edition. Geneva: World Health Organisation.

    9. WHO (2011) Comprehensive guidelines for the prevention and control of dengue and dengue haemorrhagic fever, revised and expanded edition. In: Asia ROfS-E, editor. Delhi.

    10. India Go (2008) Guidelines for clinical management of dengue fever, dengue haemorrhagic fever and dengue shock syndrome. In: Programme DoNVBDC , editor. Delhi.

  • Related Research Results (2)
  • Metrics
    No metrics available
Share - Bookmark